Johnson & Johnson announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first volunteers have received their initial vaccine dose.
Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, writes in a new blog about progress being made to help communities in West Africa that were devastated by the Ebola outbreak. While Ebola cases have declined, Dr. Stoffels says preparedness is the key to prevent future outbreaks.
When the World Health Organization declared Ebola a global health crisis last year, Johnson & Johnson announced it would fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the Ebola outbreak.
Welcome to the Johnson & Johnson corporate website home page. The stories on this page are inspired by our commitment to caring for the health and well-being of people around the world.